Malondialdehyde Antikörper

Produktnummer ABIN5067343

Produktdetails anti-Malondialdehyde Antikörper

Target: Malondialdehyde (MDA)

Reaktivität: Bitte anfragen

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Malondialdehyde Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunocytochemistry (ICC), Flow Cytometry (FACS), Immunofluorescence (IF)

Spezifität: Specific for MDA conjugated proteins. Does not detect free MDA. Does not cross-react with Acrolein, Crotonaldehyde, Hexanoyl Lysine, 4-HHE, 4-HNE, or Methylglyoxal modified proteins.

Aufreinigung: Protein G Purified

Immunogen: Synthetic Malondialdehyde modified Keyhole Limpet Hemocyanin (KLH).

Klon: 6H6

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise:

• WB (1:1000)
• ICC/IF (1:50)
• FACS (1:50)
• FCM (1:50)
• ELISA (1:1000)
• optimal dilutions for assays should be determined by the user.

Kommentare:

A 1:1000 dilution of ABIN5067343 was sufficient for detection of Malondialdehyde in 2 μg of Malondialdehyde conjugated to BSA by ECL immunoblot analysis using Goat Anti-Mouse IgG:HRP as the secondary Antibody.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS pH 7.4, 50 % glycerol, 0.09 % Sodium azide, Storage buffer may change when conjugated

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: -20°C

Details zu Malondialdehyde

Target: Malondialdehyde (MDA)

Andere Bezeichnung: Malondialdehyde (MDA Produkte)

Substanzklasse: Chemical

Hintergrund: Malondialdehyde (MDA) is the biomarker in greatest diagnostic use, due to its molecular stability. This three-carbon, low-molecular weight aldehyde has a strong affinity for amino acids, which results in adduct formation to both free amino acids and proteins. Increased MDA levels have been found at correlating levels in breast cancer, and lung cancer patients. Other diseased states with elevated MDA levels include diabetes and Alzheimer's disease. Multiple laboratory techniques exist for quantification of MDA levels, including the thiobarbituric acid reactive substances (TBARS) assay. In addition to use as a biomarker, MDA has been shown to have mutagenic effects on tissues themselves as adduct formation can result in DNA cross-linking.